Propanc Biopharma, Inc. - Common Stock (PPCB)

Plans to File CTA for Ph. 1b, FIH Study, 30 – 40 Advanced Cancer Patients in ‘26

Provides End-To-End Services for Preclinical & Clinical Projects with Extensive Experience in Decoding Biologics Production

Entering a Transformative Stage by Advancing PRP to a Pivotal, Phase 1b, FIH, Clinical Study Whilst Undertaking Additional Research into Age-Related Chronic Diseases

MELBOURNE, Australia , May 13, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced that its Board of Directors on March 16, 2026, approved a 1-for-25 reverse stock split of the Company's issued and outstanding shares of common stock, par value $0.001 per share, (the “Reverse Stock Split”). The Reverse Stock Split is anticipated to be effective as of the open of the market May 18, 2026.

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Propanc Biopharma Inc. (NASDAQ: PPCB) resulting from allegations that Propanc may have issued materially misleading business information to the investing public.

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Propanc Biopharma Inc. (NASDAQ: PPCB) resulting from allegations that Propanc may have issued materially misleading business information to the investing public.

Fifth Agreement between Propanc & the Universities over a 17yr Period

Root-Cause Attack. Chemo Sensitization. Safer Profile.

A German CDO Supporting Biotech Companies Bringing Biologics from Early Development to Clinic

PRP May Outshine Traditional Therapies in a Booming $4.4 Billion Market

MELBOURNE, Australia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel treatments for recurrent and metastatic cancer, today announced an update on corporate progress and reported half yearly financial results as of December 31, 2025 (Year end June 30).

MELBOURNE, Australia, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today highlighted the potential of its lead proenzyme therapy, PRP, as a novel approach that could compete with existing approved therapies for solid tumors, particularly in areas of high unmet need such as pancreatic cancer.

Key Milestone Builds Toward Doubling Patent Portfolio to Over 200 Worldwide – Positioning Propanc as a Long-Term Leader in Metastatic Cancer Prevention

A World-First, Fully Synthetic Recombinant Version of PRP

The Science, Clinical Promise, & Market Outlook

CEO Highlights Significant Progress Achieved & Outlines Ambitious Plans for 2026

Joint Research Team Focusing on Impact of PRP Reversal of EMT Pathways as Central Role

Results Underscore PRP Candidacy as a Disruptor of the Tumor Microenvironment